PCOS Has a New Name… Here’s Why It Matters
Updated: Sep 21
PCOS Has a New Name and Here’s Why It Matters
“What’s in a name?” When it comes to medicine, quite a lot.
Polycystic Ovary Syndrome (PCOS), a hormonal and metabolic condition affecting approximately one in eight women, officially has a new name: Polyendocrine Metabolic Ovarian Syndrome (PMOS). ¹
The change follows a rigorous global consensus process published in The Lancet in May 2026. Led by the Global Name Change Consortium, the process involved 56 leading academic, clinical, and patient organizations and included 14,360 survey responses from people living with PCOS and multidisciplinary health professionals around the world. ¹ The goal was to find a name that more accurately represents the condition while reducing confusion and stigma.
The consensus concluded that “polycystic ovary syndrome" no longer accurately reflects what we know about the condition. The old name places too much emphasis on ovarian “cysts,” while overlooking the broader endocrine and metabolic features that can affect health throughout the body. PMOS is now the consensus new name, with a three-year managed transition underway to support its adoption across healthcare, research, education, and public communication. ¹
A 2026 editorial by endocrinologist Dr. Maria Dalamaga, published in Metabolism Open, further discusses the reasoning behind this change, including its potential to improve diagnostic thinking, clinical care, research priorities, and how patients understand their health.²
But why does changing the name matter?
The Problem with the Name “Polycystic Ovary Syndrome”
Many people assume that PCOS is simply a condition involving ovarian cysts. In reality, this is a common misconception. The “cysts” associated with PCOS are not true pathological ovarian cysts. The old terminology placed an outsized focus on ovarian morphology, despite the condition involving much more than the ovaries.¹
This distinction is especially important because ovarian findings alone do not determine whether someone has PMOS. In adults, diagnosis is based on meeting at least two of three criteria after other possible causes are excluded: irregular or absent ovulation, clinical or biochemical signs of elevated androgens, and polycystic ovarian morphology on ultrasound or elevated anti-Müllerian hormone (AMH). ¹
This means that someone can meet the diagnostic criteria without having polycystic ovaries visible on an ultrasound. By removing “polycystic” from the name, PMOS helps move attention away from the misconception that ovarian “cysts” are necessary for diagnosis.
The new terminology instead recognizes what is actually a multisystem condition involving ovarian, endocrine, and metabolic function. ¹
PCOS Is More Than a Reproductive Condition
Our understanding of the condition has expanded far beyond fertility and the ovaries. PMOS is associated with a range of endocrine and metabolic concerns, including insulin resistance, abnormal cholesterol levels, type 2 diabetes, cardiovascular risk, and fatty liver disease. Mental health concerns, including anxiety and depression, can also be part of the broader experience of the condition. ²
For some individuals, metabolic concerns may be present long before reproductive concerns become the main focus. The name PMOS better reflects this broader understanding by recognizing that the condition involves interconnected systems throughout the body.
Why the New Name Matters
The new name, Polyendocrine Metabolic Ovarian Syndrome (PMOS), was selected through the global consensus process because each part more accurately represents the condition. ¹
Polyendocrine recognizes that multiple endocrine and hormonal processes are involved.
Metabolic highlights the important role of metabolic health and concerns such as insulin resistance.
Ovarian acknowledges that ovarian function remains an important part of the condition without suggesting that ovarian cysts define it.
Syndrome reflects the fact that PMOS can present differently from person to person.
Rather than defining the condition by one potentially misleading ovarian feature, PMOS better captures its endocrine, metabolic, and ovarian complexity.
Better Names Can Lead to Better Care
Changing medical terminology is about much more than updating a name.
The editorial explains that disease names influence how healthcare providers think about diagnosis, what researchers choose to investigate, how health policies are developed, and how patients understand their own bodies and health.
The global consensus process identified several problems associated with the PCOS name, including confusion around ovarian cysts, stigma, delayed diagnosis, fragmented care, and an incomplete representation of the condition’s endocrine and metabolic features. ¹
By more accurately representing the condition, PMOS may encourage healthcare professionals and patients to look beyond reproductive symptoms and consider metabolic and endocrine health as important parts of long-term care.
What Happens During the Transitoin?
Although PMOS is now the consensus new name, changing terminology that has been used for decades will not happen overnight.
PCOS appears throughout clinical guidelines, medical records, research literature, textbooks, patient resources, and healthcare systems worldwide. Rather than treating PMOS as an entirely new condition, the consensus group recommended an evolutionary transition that maintains continuity with the existing body of PCOS knowledge. ¹
A three-year managed transition period is now underway. The implementation strategy includes developing patient and healthcare-professional resources, updating education and communication materials, integrating the terminology into healthcare information systems, engaging research and policy organizations, and working toward integration into international disease-classification systems. ¹
During this period, patients may continue to see both PCOS and PMOS used as healthcare systems gradually adopt the new terminology.
Looking Ahead
The transition from PCOS to PMOS reflects something bigger than a change in terminology: our understanding of the condition has evolved.
From a naturopathic perspective, this whole-person approach is not new. Naturopathic medicine has long recognized that hormonal health cannot be viewed in isolation from metabolism, nutrition, sleep, stress, movement, and other aspects of an individual’s overall health.
For naturopathic care, the name change may therefore feel less like a change in philosophy and more like the broader medical language beginning to reflect an interconnected approach that has long informed whole-person care.
Where PMOS may have its greatest impact is in changing how the condition is understood across the wider healthcare system, research, education, and public health. A name that recognizes endocrine, metabolic, and ovarian health together may help patients better understand their diagnosis while encouraging more comprehensive conversations about their long-term health.
Sometimes, changing a name is the first step toward changing the conversation.
Written by Diya Mani, a student contributor for Reclaim Wellness Clinic. This article was reviewed and edited by Dr. Maya Matthews, ND.
Dr. Maya's Thoughts
As a Naturopathic Doctor focused on women's hormone health, I see a lot of women with PCOS feeling lost and confused about treatment. They're wondering if it's a hormone problem or a blood sugar problem, and what to work on first.
I love when the medical community comes up with a name for a condition that is both empowering and validating for women dealing with PCOS/PMOS.
With the Reclaim Method treatment approach, we aren't just chasing hormones. We're diving deeper into the metabolism, stress, and inflammation that patients are coming in with.
Ultimately, everyone's treatment is customized based on the 5 pillars of the Reclaim Method, and I typically see PMOS fit within the hormones and blood sugar pillars, you can read more about my approach for PMOS/PCOS here.
I'm loving that we're seeing so many advancements in women's health. From the renaming of PMOS to HRT acceptance and rollout, women are starting to get better access to health care and empowerment with their bodies.
If you'd like to learn more about how the Reclaim Method can help break down your main concerns and come up with a plan to get you moving forward, book a complimentary Hormone Breakthrough Call with me.
In that call, we'll go through what's been going on with your health, what your main goals are, and what sort of options we have to get there.
References
1. Teede, H. J., Bahri Khomami, M., Morman, R., Laven, J. S. E., Joham, A. E., Costello, M. F., Patil, M., Rees, D. A., Berry, L., Cree, M. G., Zhao, H., Norman, R. J., Dokras, A., Piltonen, T., & Global Name Change Consortium. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: A multistep global consensus process. The Lancet, 407(10545), 2329–2339.
2. Dalamaga, M. (2026). What’s in a name? From PCOS to polyendocrine metabolic ovarian syndrome: A metabolic reframing, promise, controversies, and challenges ahead. Metabolism Open, 30, 100479.
